Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

Dow Jones01-14

1215 ET - Merck & Co. CEO Rob Davis is bullish about the company's ability to drive growth once the company's exclusive rights to Keytruda expires in 2028, he said Monday at the JPMorgan Healthcare Conference. "My confidence that we will see it be a shallow fall followed by growth in a few years is quite high," Davis says. Over the next 18 to 24 months, the company is targeting 30% to 40% adoption of Keytruda Qlex, an injectable form of Keytruda which received FDA approval in September. "That would put us out about the period of time, depending on what happens with the LOE, to be in a situation that we have that at the time that we lose exclusivity," Davis says. (elias.schisgall@wsj.com)

(END) Dow Jones Newswires

January 13, 2026 12:15 ET (17:15 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment